1. XTENT

XTENT, Inc. XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). ...

2. Highlights of IR Studies at SIR 2010
(Radiology Conferences/SIR 2010)

... Promise: Drug-Eluting Stents for Critical Limb Ischemia New Science Treating Peripheral Arterial Disease: Stem Cell Therapy Advances Source: SIR You can discuss about SIR conference and related topic ...

3. ACC: Novel Stents May be More Effective
(Radiology Conferences/Conference News)

Two new stent designs appear at least as safe as prior generations with some efficacy advantages, according to trials reported here at the American College of Cardiology (ACC). A novel dual drug-eluting, ...

4. MEDRAD - B. Braun: Co-marketing & Trademark License Agreement
(Company News/MEDRAD)

... (CAD). The Paccocath technology will be used in both MEDRAD 's and B. Braun's drug-eluting balloons. Under the agreement, B. Braun is permitted to use the Paccocath trademark in connection with promotion ...

5. Medtronic Acquires Invatec & Affiliated Companies
(Company News/Medtronic)

... Notably, Invatec has brought four drug-eluting balloons to market, covering the coronaries and lower-extremity vessels – the only company worldwide with this distinction. It is a pioneer in the development ...

6. Volcano's Installed Base Growth Milestone Attained
(Company News/Volcano)

... period a year ago. These tools are being increasingly relied upon by physicians who continue to look for ways to improve on current drug-eluting stent (DES) outcomes, especially in more complex lesions ...

7. Medtronic Hires Renowned Cardiologist as VP
(Company News/Medtronic)

... of Medtronic’s Endeavor® drug-eluting coronary stents. In addition, Prof. Rothman has led cardiac stem cell research for heart failure treatment. He also established the largest heart attack center in ...

8. An Analysis of Medical Device Industry in China With Reference to The Chinese Healthcare Reform
(Healthcare Reform/Healthcare Reform)

... complicated heart surgery.  The market for angioplasty and stents, especially drug-eluting stents, is taking off and there are already several domestic companies seeking to gain market share. Every year, ...

9. CRF Announces Late Breaking Trials to be Presented at TCT 2009
(Radiology Conferences/TCT 2009)

...  DEBATER: A Prospective Randomized Trial of Drug-Eluting vs. Bare-Metal Stents With or Without Abciximab in STEMI HORIZONS AMI: Two-Year Follow-up from a Prospective Randomized Trial of Heparin Plus Glycoprotein ...

10. New Data on Endeavor Stent's Long-Term Safety and Efficacy to Be Featured at Interventional Cardiology Congress
(Company News/Medtronic)

... 2009 PCR meeting that feature the company’s cardiovascular innovations. From late breaking clinical trials, extensive new data on the Endeavor Drug-Eluting Stent (DES) will be presented, which shows unprecedented ...

11. Bypass May be Less Dangerous for Older Diabetics than Angioplasty: Study Shows
(Communities/Cardiac Vasculature)

... if treated with (bypass)," they wrote. And patients under 55 were 25 percent more likely to die with bypass than with angioplasty. None of the trials used the newer, drug-eluting stents, which release ...

12. AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics
(Healthcare Informatics/Healthcare Informatics)

... topics included on the CHAIN Web site address the management of blood clot prevention with drug-eluting stents and expert opinions about topics where evidence is uncertain, such as restarting antiplatelet ...

13. First Use in a Patient of The InfraReDx LipiScan Coronary Imaging System
(Company News/InfraReDx)

... with severe narrowings. Based on further research, this novel device may help determine which type of stent – bare metal or drug-eluting — is best for the patient.” The U.S. Food and Drug Administration ...

14. Innovative technologies promise new solutions to cardiology's challenges
(Imported/Imported)

... Medical Center, Mount Scopus, Jerusalem, Israel. "Our findings using the CAPSID device with bare-metal stents are similar to results obtained with drug-eluting stents, without their increased cost and ...

15. Investigations focus on illegal marketing by medical device and supply companies
(Imported/Imported)

... over documents as part of an investigation into the off-label marketing of the new drug-eluting stents implanted in patients with heart disease approved in the US for less than 3 years. In December 2006, ...

16. New biodegradable magnesium stents for coronary arteries
(Imported/Imported)

... stents fitted. And drug-eluting stents have limitations because despite being able to achieve significant decreases in angiographic restenosis, they can cause hypersensitivity reactions and late-stent ...

17. New data reassures on safety of drug-coated stents
(Imported/Imported)

... said on Sunday. Fears that patients might do worse on so-called drug-eluting stents than on older bare metal ones have led to a $1bn slump in sales in the past year, hurting leading manufacturers like ...

18. Swiss study finds Johnson and Johnson's stent better than Boston's
(Imported/Imported)

... was compelling, but Boston Scientific argued it was flawed, and some outside experts also questioned the attempt to compare the two drug-eluting brands. The independent analysis, involving records from ...

19. Stanford analysis shows little difference in risk rates for angioplasty, bypass procedures
(Imported/Imported)

... angioplasties involving stents coated with drugs that are released over time, which may reduce the chance that arteries will become clogged again. Because these drug-eluting stents are relatively new, ...

20. What’s more important in medicine: diagnostics, therapeutics or prognosis?
(Radiology News/Radiology Articles)

... being a traditional pharmaceutical company to being an integrated innovator in a number of lines of medical technology. Abbott has entered the device sector – most notably the drug-eluting stent (DES) ...